Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT05207371
PHASE1/PHASE2

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

Sponsor: GAIA BioMedicine Inc.

View on ClinicalTrials.gov

Summary

Phase I Part : Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II. Phase II Part : Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.

Official title: Phase I / II Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

Key Details

Gender

All

Age Range

20 Years - Any

Study Type

INTERVENTIONAL

Enrollment

22

Start Date

2021-12-01

Completion Date

2026-03-06

Last Updated

2026-09-03

Healthy Volunteers

No

Interventions

BIOLOGICAL

Biological

Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)

Locations (3)

Kyushu University Hospital

Fukuoka, Fukuoka, Japan

Kitakyushu Municipal Medical Center

Kitakyushu, Fukuoka, Japan

Kurume University Hospital

Kurume, Fukuoka, Japan